IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma

In the DONIMI trial, a baseline IFN-γ signature enables prospective selection of patients who can benefit from anti-PD-1 monotherapy. In contrast to results of our murine melanoma model, domatinostat (a class I HDAC inhibitor) does not add benefit to neoadjuvant anti-PD-1 ± anti-CTLA-4 in patients.

• Publication year

  2023

• Venue

  Journal of Experimental Medicine

• Publication date

  2023-03-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1084/jem.20221952PMID 36920329PMCID 10037109
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.

  2023cited by this paper
• Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

  2022cited by this paper
• Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.

  2022cited by this paper
• MeVa2.1.dOVA and MeVa2.2.dOVA: two novel BRAFV600E-driven mouse melanoma cell lines to study tumor immune resistance

  2022cited by this paper
• Neoadjuvant relatlimab and nivolumab in resectable melanoma

  2022cited by this paper
• Entinostat induces antitumor immune responses through immune editing of tumor neoantigens.

  2021cited by this paper
• Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

  2021cited by this paper
• Results from the phase Ib of the SENSITIZE trial combining domatinostat with pembrolizumab in advanced melanoma patients refractory to prior checkpoint inhibitor therapy.

  2021cited by this paper
• Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

  2021cited by this paper
• Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma.

  2021cited by this paper
• Targeting pan-essential genes in cancer: challenges and opportunities.

  2020cited by this paper
• Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma

  2020cited by this paper
• First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.

  2020cited by this paper
• A Single Dose of Neoadjuvant PD-1 Blockade Predicts Clinical Outcomes in Resectable Melanoma

  2019cited by this paper
• Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME)

  2019influential reference
• HDAC3 Inhibition Upregulates PD-L1 Expression in B-Cell Lymphomas and Augments the Efficacy of Anti–PD-L1 Therapy

  2019cited by this paper
• Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

  2018cited by this paper
• Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma

  2018cited by this paper
• Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma

  2018cited by this paper
• Modulation of antitumor immunity with histone deacetylase inhibitors.

  2017cited by this paper
• IFN-&ggr;–related mRNA profile predicts clinical response to PD-1 blockade

  2017cited by this paper
• Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease

  2016cited by this paper
• A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma

  2016cited by this paper
• Phase II trial of vorinostat in advanced melanoma

  2014cited by this paper
• Exposure to a Histone Deacetylase Inhibitor Has Detrimental Effects on Human Lymphocyte Viability and Function

  2014cited by this paper
• Oncology meets immunology: the cancer-immunity cycle.

  2013cited by this paper
• Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models

  2012cited by this paper
• Generation of Peptide MHC Class I Monomers and Multimers Through Ligand Exchange

  2009cited by this paper
• Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824.

  2009influential reference
• Blockade of PD‐L1 (B7‐H1) augments human tumor‐specific T cell responses in vitro

  2006cited by this paper
• PD-L2 is a second ligand for PD-1 and inhibits T cell activation

  2001cited by this paper

• Insights into RAS-driven melanoma and its therapeutic implications.

  2026cites this paper
• Treatment effect of neoadjuvant immunotherapy in melanoma correlates with tumor burden: meta-analysis of reported clinical trials.

  2026cites this paper
• Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.

  2026cites this paper
• Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort.

  2025cites this paper
• Role of Surgery for Metastatic Melanoma in the Era of Checkpoint Blockade.

  2025cites this paper
• Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB–D melanoma: a phase 1/2 trial

  2025cites this paper
• Evaluating two rechallenge strategies of immune checkpoint inhibitors: Durvalumab plus tremelimumab in advanced hepatocellular carcinoma

  2025cites this paper
• Neoadjuvant or perioperative immunotherapy for resectable melanoma: The need for biomarkers.

  2025cites this paper
• Multimodal integration of blood RNA and ctDNA reflects response to immunotherapy in metastatic urothelial cancer

  2025cites this paper
• Threading the Needle: Navigating Novel Immunotherapeutics in Pancreatic Ductal Adenocarcinoma

  2025cites this paper
• Predictive Biomarkers for Immune Checkpoint Inhibitor Therapy in Advanced Melanomas.

  2025cites this paper
• Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols

  2025cites this paper
• Dual role of interferon-gamma in the response of melanoma patients to immunotherapy with immune checkpoint inhibitors

  2025cites this paper
• Soluble CD27 differentially predicts resistance to anti-PD1 alone but not with anti-CTLA-4 in melanoma

  2025cites this paper
• Harnessing Histone Deacetylase Inhibitors for Enhanced Cancer Immunotherapy.

  2025cites this paper
• Macrophage sensitivity to bexmarilimab-induced reprogramming is shaped by the tumor microenvironment

  2025cites this paper
• A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study

  2025cites this paper
• Japanese Dermatological Association Guidelines: Clinical Questions of Guidelines for Melanoma 2025

  2025cites this paper
• Transforming Clinical Trials in Skin Cancer Research: Exploring the Potential of Flexible and Innovative Designs.

  2025cites this paper
• The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types

  2025cites this paper
• Dissecting response to neoadjuvant immunotherapy-treated melanoma using cancer-immunity cycle-associated signatures

  2025cites this paper
• Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB–D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915

  2025cites this paper
• Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: A nationwide real-life study in France (NEOMEL).

  2025cites this paper
• Neoadjuvant immune checkpoint inhibition improves protection against hepatic melanoma metastasis.

  2025cites this paper
• IFNγ-induced PD-L1+MHC II+ macrophages and Tim-3+ tumor-reactive CD8+ T cells predict a response to anti-PD-1 therapy in tumor-bearing mice.

  2025cites this paper
• Nail toxicities associated with cancer therapies: Insights and recommendations from the EADV task force dermatology for cancer patients

  2025cites this paper
• Activation of T cell-intrinsic p53 by acetylation elicits antitumor immunity to boost cancer immunotherapy.

  2025cites this paper
• Lessons from neoadjuvant immunotherapy in melanoma: understanding antitumour immunity and tumour escape

  2025cites this paper
• Transforming cancer immunotherapy: integration of distinct immune-based approaches as redefined dual immunotherapy with potential third-sensitizer

  2025cites this paper
• Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial

  2025cites this paper
• Immune monitoring of neoadjuvant chemo-immunotherapy for triple-negative breast cancer

  2025cites this paper
• Circulating IFNγ-associated protein signatures predict response to neoadjuvant immunotherapy in patients with stage III melanoma

  2025cites this paper
• Toward Personalized Response Monitoring in Melanoma Patients Treated with Immunotherapy and Target Therapy

  2025cites this paper
• Current and emerging opportunities for deintensification of systemic therapies in melanoma: A scoping review.

  2025cites this paper
• Dual role of IFNγ in reprogramming the undifferentiated pleomorphic sarcoma cell line JBT19 towards cytotoxic chemotherapy and antitumor immunity

  2025cites this paper
• Immune signature-based uncoupling of checkpoint inhibitor efficacy and toxicity.

  2025cites this paper
• Antigen-specific profiling identifies T-bet+ melanoma-specific CD8+ T cells associated with response to neoadjuvant PD-1 blockade.

  2025cites this paper
• The emergence of neoadjuvant immune‐ over BRAF therapy in melanoma

  2024cites this paper
• Advances in Adjuvant and Neoadjuvant Therapy for Melanoma.

  2024cites this paper
• Interferon-γ driven differentiation of monocytes into PD-L1+ and MHC II+ macrophages and the frequency of Tim-3+ tumor-reactive CD8+ T cells within the tumor microenvironment predict a positive response to anti-PD-1-based therapy in tumor-bearing mice

  2024cites this paper
• Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial

  2024cites this paper
• Leveraging the potential for deintensification in cancer care

  2024cites this paper
• Salivary biomarkers: a promising approach for predicting immunotherapy response in head and neck cancers

  2024cites this paper
• Epigenetics-targeted drugs: current paradigms and future challenges

  2024cites this paper
• Polymeric Multivalent Fc Binding Peptides‐Fabricated Clinical Compounding Bispecific Antibody Potentiates Dual Immunotherapy Targeting PD1 and CTLA‐4

  2024cites this paper
• Prognostic Biomarkers in Evolving Melanoma Immunotherapy

  2024cites this paper
• Neoadjuvant Therapy in Melanoma: Current Evidence and Future Directions of Investigation.

  2024cites this paper
• Neoadjuvant Therapy: Changes in the Management of Macroscopic Stage III/Resectable Stage IV Melanoma.

  2024cites this paper
• AIM2 promotes irradiation resistance, migration ability and PD-L1 expression through STAT1/NF-κB activation in oral squamous cell carcinoma

  2024cites this paper
• Guanylate binding protein 5 triggers NF-κB activation to foster radioresistance, metastatic progression and PD-L1 expression in oral squamous cell carcinoma.

  2024cites this paper
• Precision Oncology in Melanoma and Skin Cancer Surgery.

  2024cites this paper
• Effect of anti-COVID-19 drugs on patients with cancer.

  2024cites this paper
• Rapidly Evolving Pre- and Post-surgical Systemic Treatment of Melanoma

  2024cites this paper
• The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrations.

  2024cites this paper
• Selective activation of IFNγ-ipilimumab enhances the therapeutic effect and safety of ipilimumab.

  2024cites this paper
• Molecular and Clinicopathological Biomarkers in the Neoadjuvant Treatment of Patients with Advanced Resectable Melanoma

  2024influential citation
• Neo-Adjuvant Therapy for Metastatic Melanoma

  2024cites this paper
• Prognostic biomarkers in melanoma: a 2023 update from clinical trials in different therapeutic scenarios

  2024cites this paper
• Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours

  2024cites this paper
• Exploiting temporal aspects of cancer immunotherapy

  2024influential citation
• Targeting cytokine and chemokine signaling pathways for cancer therapy

  2024cites this paper
• IFNγ score–based neoadjuvant immunotherapy for stage III melanoma

  2023cites this paper
• Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma

  2023cites this paper
• Clinical updates in neoadjuvant immunotherapy for melanoma before surgery

  2023cites this paper
• Biomarker-Driven Personalization of Neoadjuvant Immunotherapy in Melanoma.

  2023cites this paper
• Correlations between inflammatory cytokine levels and degree of pigmentation in acral melanomas

  2023cites this paper
• Facts and Hopes in Neoadjuvant Immunotherapy: Current Approvals and Emerging Evidence.

  2023cites this paper
• Quoi de neuf en oncodermatologie ?

  2023cites this paper
• Prognostic and predictive biomarkers in melanoma.

  2023cites this paper
• The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role?

  2023cites this paper
• Predictive Factors in Metastatic Melanoma Treated with Immune Checkpoint Inhibitors: From Clinical Practice to Future Perspective

  2023cites this paper
• Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now.

  2023cites this paper
• PD1 monotherapy reigns supreme in adjuvant melanoma…but for how long?

  2023cites this paper